BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 36442564)

  • 21. Casp8 acts through A20 to inhibit PD-L1 expression: The mechanism and its implication in immunotherapy.
    Zou J; Xia H; Zhang C; Xu H; Tang Q; Zhu G; Li J; Bi F
    Cancer Sci; 2021 Jul; 112(7):2664-2678. PubMed ID: 33934451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spatiotemporally co-delivery of triple therapeutic drugs via HA-coating nanosystems for enhanced immunotherapy.
    Ma C; Duan Y; Wu C; Meng E; Li P; Zhang Z; Zang C; Ren X
    Asian J Pharm Sci; 2021 Sep; 16(5):653-664. PubMed ID: 34849170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Folic acid-functionalized polyethylenimine superparamagnetic iron oxide nanoparticles as theranostic agents for magnetic resonance imaging and PD-L1 siRNA delivery for gastric cancer.
    Luo X; Peng X; Hou J; Wu S; Shen J; Wang L
    Int J Nanomedicine; 2017; 12():5331-5343. PubMed ID: 28794626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines.
    Ji S; Lee J; Lee ES; Kim DH; Sin JI
    Hum Vaccin Immunother; 2021 Jul; 17(7):1910-1922. PubMed ID: 33522416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma.
    van Duijn A; Willemsen KJ; van Uden NOP; Hoyng L; Erades S; Koster J; Luiten RM; Bakker WJ
    Cancer Immunol Immunother; 2022 Mar; 71(3):529-540. PubMed ID: 34268602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.
    Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A
    Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects.
    Xu L; Zhang Y; Tian K; Chen X; Zhang R; Mu X; Wu Y; Wang D; Wang S; Liu F; Wang T; Zhang J; Liu S; Zhang Y; Tu C; Liu H
    J Exp Clin Cancer Res; 2018 Oct; 37(1):261. PubMed ID: 30373602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-tumor immunity and ferroptosis of hepatocellular carcinoma are enhanced by combined therapy of sorafenib and delivering modified GO-based PD-L1 siRNAs.
    Li Z; Bu J; Zhu X; Zhou H; Ren K; Chu PK; Li L; Hu X; Ding X
    Biomater Adv; 2022 May; 136():212761. PubMed ID: 35929305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway.
    Li X; Wang S; Mu W; Barry J; Han A; Carpenter RL; Jiang BH; Peiper SC; Mahoney MG; Aplin AE; Ren H; He J
    J Exp Clin Cancer Res; 2022 Jan; 41(1):41. PubMed ID: 35086548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer.
    Zhang R; Zhu Z; Lv H; Li F; Sun S; Li J; Lee CS
    Small; 2019 Dec; 15(49):e1903881. PubMed ID: 31702880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An inhibitor of programmed death ligand 1 enhances natural killer cell-mediated immunity against malignant melanoma cells.
    Lee YS; Heo W; Choi HJ; Cho HR; Nam JH; Ki YG; Lee HR; Son WC; Park YS; Kang CD; Bae J
    PLoS One; 2021; 16(4):e0248870. PubMed ID: 33793576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle.
    Li C; Han X
    Pharm Res; 2020 May; 37(6):109. PubMed ID: 32476052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
    Chen X; Wang K; Jiang S; Sun H; Che X; Zhang M; He J; Wen Y; Liao M; Li X; Zhou X; Song J; Ren X; Yi W; Yang J; Chen X; Yin M; Cheng Y
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Novel Polysaccharide Separated from Panax Notoginseng Residue Ameliorates Restraint Stress- and Lipopolysaccharide-induced Enteritis in Mice.
    Luo B; Yang F; Chen P; Zuo HY; Liang YF; Xian MH; Tang N; Wang GE
    Chem Biodivers; 2023 Oct; 20(10):e202300648. PubMed ID: 37615232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using
    Liechtenstein T; Perez-Janices N; Blanco-Luquin I; Goyvaerts C; Schwarze J; Dufait I; Lanna A; Ridder M; Guerrero-Setas D; Breckpot K; Escors D
    Oncoimmunology; 2014; 3(7):e945378. PubMed ID: 25954597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion.
    Voli F; Valli E; Lerra L; Kimpton K; Saletta F; Giorgi FM; Mercatelli D; Rouaen JRC; Shen S; Murray JE; Ahmed-Cox A; Cirillo G; Mayoh C; Beavis PA; Haber M; Trapani JA; Kavallaris M; Vittorio O
    Cancer Res; 2020 Oct; 80(19):4129-4144. PubMed ID: 32816860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.